Potent immunosuppressive effects of the oncometabolite R-2-hydroxyglutarate

Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal

(2018) Samra Turajlic et al.   CELL

Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis

(2018) Chong Hyun Suh et al.   EUROPEAN RADIOLOGY

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate

(2018) Lukas Bunse et al.   NATURE MEDICINE

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

(2018) Courtney D. DiNardo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Spermidine in health and disease

(2018) Frank Madeo et al.   SCIENCE

D-2-hydroxyglutarate interferes with HIF-1α stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polarization

(2018) Martin Böttcher et al.   OncoImmunology

The hallmarks of successful anticancer immunotherapy

(2018) Lorenzo Galluzzi et al.   Science Translational Medicine

Resisting fatal attraction: a glioma oncometabolite prevents CD8+ T cell recruitment

(2017) Liliana E. Lucca et al.   JOURNAL OF CLINICAL INVESTIGATION

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas

(2017) Gary Kohanbash et al.   JOURNAL OF CLINICAL INVESTIGATION

Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

(2017) Christopher Abbosh et al.   NATURE

The immune contexture in cancer prognosis and treatment

(2017) Wolf H. Fridman et al.   Nature Reviews Clinical Oncology

Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance

(2016) Federico Pietrocola et al.   CANCER CELL

Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma

(2016) Changho Choi et al.   JOURNAL OF CLINICAL ONCOLOGY

S-2-hydroxyglutarate regulates CD8+ T-lymphocyte fate

(2016) Petros A. Tyrakis et al.   NATURE

The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells

(2016) Jing-Yi Chen et al.   Scientific Reports

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

(2015) Lorenzo Galluzzi et al.   CANCER CELL

2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling

(2015) Xudong Fu et al.   Cell Metabolism

Acetyl Coenzyme A: A Central Metabolite and Second Messenger

(2015) Federico Pietrocola et al.   Cell Metabolism

Natural and therapy-induced immunosurveillance in breast cancer

(2015) Guido Kroemer et al.   NATURE MEDICINE

Metabolic targets for cancer therapy

(2013) Lorenzo Galluzzi et al.   NATURE REVIEWS DRUG DISCOVERY

IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives

(2012) H. Yang et al.   CLINICAL CANCER RESEARCH

The secret ally: immunostimulation by anticancer drugs

(2012) Lorenzo Galluzzi et al.   NATURE REVIEWS DRUG DISCOVERY

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

(2010) Patrick S. Ward et al.   CANCER CELL

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

(2010) Maria E. Figueroa et al.   CANCER CELL

IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication

(2010) Peter Paschka et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE